Compare LTRX & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTRX | MIST |
|---|---|---|
| Founded | 1989 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.5M | 163.2M |
| IPO Year | 2000 | N/A |
| Metric | LTRX | MIST |
|---|---|---|
| Price | $5.55 | $2.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $5.17 | ★ $6.33 |
| AVG Volume (30 Days) | 299.4K | ★ 3.5M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $118,294,000.00 | N/A |
| Revenue This Year | $4.59 | N/A |
| Revenue Next Year | $12.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.91 | $0.63 |
| 52 Week High | $5.89 | $2.77 |
| Indicator | LTRX | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 64.57 | 70.83 |
| Support Level | $4.88 | $2.52 |
| Resistance Level | $5.89 | $2.75 |
| Average True Range (ATR) | 0.31 | 0.19 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 77.18 | 86.54 |
Lantronix Inc is a networking company. It provides secure data access and management solutions for the Internet of Things (IoT) and information technology assets. It organizes its products and solutions into three product lines: Embedded IoT Solutions, IoT Systems Solutions, and Software and Services. The IoT System Solutions segment is the key revenue driver for the company. The company serves a diverse range of markets including healthcare, industrial, security, energy, transportation, and government networking. Its primary geographic markets are the Americas, Europe, the Middle East and Africa, and Asia Pacific Japan. The Americas contribute the vast majority of total revenue.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).